NCT03549260 - Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 22, 2018

Primary Completion Date

November 9, 2018

Study Completion Date

November 30, 2018

Conditions

LDL Cholesterol

Interventions

BIOLOGICAL

LIB003

LIB003 or placebo

Trial Locations (5)

Louisville Metabolic and Atherosclerosis Research Center, Louisville

Sterling Research Group, Cincinnati

The Lindner Research Center, Cincinnati

Metabolic & Atherosclerosis Research Center (MARC), Cincinnati

Midwest Institute For Clinical Research, Indianapolis